The Effectiveness of Silver Alginate (Algidex) Patch in the Prevention of Central Line Infections in Very Low Birth Weight Infants

Completed · Not applicable

Conditions studied: Central Line Bloodstream Infections

In brief

The purpose of this study is to determine whether silver alginate (Algidex) patch is effective in the prevention of central line infections in very low birth weight infants.

Key facts

Study ID

NCT00964093

Run by

Baylor Research Institute

People needed

100

Starts

2008-11-23

Expected to finish

2015-08-20

Last updated by the study team

2026-03-23

Who can join

Age: 0 and older, up to 0. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Infants with birth weights between 500 and 1500 grams admitted to the NICU with any of the following lines will be eligible for inclusion in this study
• umbilical arterial line (UAL)
• umbilical venous line (UVL)
• peripheral arterial line (PAL)
• peripheral long line (PLL)
• central venous line (CVL)
• Each eligible subject will be randomized to receive either standard of care or silver alginate dressing. Dressings will be changed every 7 days in accordance to current facility protocols.

You may not qualify if…

• Any infant born with a lethal abnormality or who has received topical Silver therapy will be excluded from the study.

Where it is running

• Baylor University Medical Center - Women and Children's Services — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.